Bile duct cancer trial halted after just one patient
NCT ID NCT06739252
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of chemotherapy infused directly into the liver (HAIC) plus two immunotherapy drugs (atezolizumab and bevacizumab) given before and after surgery for high-risk bile duct cancer. The goal was to see if this approach could shrink tumors and improve survival. However, the study was terminated early after enrolling only one participant, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine, oxaliplatin, 5-fluorouracil, atezolizumab, bevacizumab, capecitabine, tegafur
- What this could lead to
- If successful, this approach could improve surgical outcomes and reduce recurrence for patients with high-risk bile duct cancer.
- What could go wrong
- The trial was terminated early with only 1 participant, so results are not reliable. The combination also carries risks like immune-related side effects and liver toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peing University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a One-Two punch of heat and drainage tame inoperable bile duct cancer?
- New drug cocktail aims to outsmart untreatable bile duct cancer
- AI could spot liver cancer types and predict survival without needle biopsy
- New drug cocktails aim to stop bile duct cancer return after surgery